<DOC>
	<DOCNO>NCT00049933</DOCNO>
	<brief_summary>To examine postmenopausal woman potential interaction hormone replacement therapy blood clot factor risk cardiovascular disease heart attack stroke .</brief_summary>
	<brief_title>Hormone Replacement Therapy Prothrombotic Variants</brief_title>
	<detailed_description>BACKGROUND : Estrogens prothrombotic . Recently , Heart Estrogen/progestin Replacement Study ( HERS ) , renew interest adverse effect hormone replacement therapy ( HRT ) . In HERS , HRT well placebo prevent coronary event . In post hoc analysis , treatment associate early harm late benefit . In American Heart Association fund case-control study , potential interaction observe HRT prothrombin G20210A variant risk first myocardial infarction ( MI ) post-menopausal woman hypertension . DESIGN NARRATIVE : The study case-control design . The Group Health Cooperative ( GHC ) computerize file use identify postmenopausal woman , age 30 79 yr , incident myocardial infarction ( MI ) stroke 1/2000-12/2004 . Population-based control , sample GHC enrollment file , frequency match case age , calendar year , treat hypertension . Data collection include medical-record review , telephone interview consent subject , venous-blood collection . Standard method use assay variant allele . The GHC computerize pharmacy record serve primary source information use HRT . Data analysis involve restriction , stratification , logistic regression . Case-control case-only analysis plan . There total 600 MI case , 420 stroke case 1800 control . The primary purpose examine potential interaction hormone replacement therapy procoagulant variant risk cardiovascular event . The main variant interest : ( la ) factor XIIIA Val34Leu ; ( ib ) platelet glycoprotein ( PGP ) Jib Ile843Ser ; ( ic ) PGP IIIa Leu33Pro ; ( id ) PGP Ia C807T . The secondary aim include assessment drug-gene , risk-factor-gene gene-gene interaction risk : ( 2a ) interaction PGP IIb Ser843 , PGP lila Leu33Pro PGP Ia C807T traditional cardiovascular risk factor smoke obesity risk MI stroke ; ( 2b ) interaction three coagulation factor XIII polymorphisms PAl-1 4G/5G risk stroke woman ; ( 2c ) interaction aspirin use glycoprotein IIIa Leu33Pro risk MI stroke .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<criteria>No eligibility criterion</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>